TL;DR
Despite advances in exome sequencing (ES), over half of individuals with suspected Mendelian conditions remain undiagnosed. This paper reviews the limitations of current genetic testing and explores emerging technologies like long-read sequencing, optical genome mapping, and RNA sequencing as the "next best steps" for diagnosing these challenging cases. It provides a crucial guide for clinicians navigating the evolving landscape of genetic diagnostics beyond ES.
What Problem Does This Paper Address?
The paper tackles the persistent challenge of diagnosing Mendelian conditions, which are genetic disorders caused by mutations in a single gene. While exome sequencing (ES) has revolutionized genetic diagnostics, it still fails to provide a precise molecular diagnosis for more than 50% of individuals with suspected Mendelian conditions. This diagnostic gap stems from various factors, including technical limitations of ES, incomplete understanding of variant pathogenicity, complex gene-environment interactions, and variations in how clinical labs report findings. For non-genetics specialists, keeping up with the rapidly evolving field of diagnostic tests beyond ES and understanding their limitations is a significant hurdle. The paper aims to address this by reviewing the reasons for negative diagnostic evaluations and outlining a framework for further investigation using newer, often research-stage, technologies.
Methods
The paper is a comprehensive review and discussion of existing and emerging genetic testing technologies. It doesn't present novel experimental methods but rather synthesizes information on various approaches:
- Exome Sequencing (ES) and Reanalysis: Discusses the current standard, its limitations, and the value of reanalyzing existing ES data as new genes and analytical tools become available.
- Short-Read Genome Sequencing (srGS): Explores its advantages over ES in providing a more unbiased genome-wide view, detecting noncoding variants and structural variants (SVs).
- Targeted and Whole-Genome Long-Read Sequencing (LRS): Details technologies like PacBio and Oxford Nanopore, highlighting their ability to resolve complex regions, identify repeat expansions, and phase variants.
- Optical Genome Mapping (OGM): Describes its utility in detecting large structural variants, inversions, and translocations that are difficult for other methods.
- RNA Sequencing (RNA-seq): Explains its role in identifying variants affecting splicing or expression, even without prior knowledge of variants, and its potential for reclassifying variants of uncertain significance (VUS).
- DNA Methylation Analysis: Discusses its use in identifying "episignatures" associated with specific Mendelian conditions, particularly neurodevelopmental disorders.
- Multiomics Approaches: Emphasizes the integration of genomic, transcriptomic, epigenetic, proteomic, and metabolomic data to gain a more comprehensive understanding of disease mechanisms.
Datasets
Not discussed in the paper. The paper is a review and discussion of technologies, not an empirical study with specific datasets.
Key Insights and Ideas
- The "Undiagnosed" Population is Significant: Even with advanced ES, a substantial portion of patients with suspected Mendelian conditions remain undiagnosed, highlighting the need for next-generation approaches.
- Reanalysis is Crucial: Reanalyzing existing ES data is a cost-effective way to uncover diagnoses due to new gene discoveries, improved variant interpretation, and better bioinformatic pipelines.
- Beyond the Coding Region: Many emerging technologies (srGS, LRS, OGM, RNA-seq) are critical for interrogating non-coding regions, structural variants, and gene expression, which ES often misses.
- Complexity of Variants: Identifying and interpreting variants in challenging regions (e.g., repetitive sequences, deep introns) requires specialized technologies.
- Multi-omics is the Future: Integrating different data types (genomics, transcriptomics, epigenomics, etc.) offers a more holistic view and can be particularly powerful for complex or mitochondrial disorders.
- Clinical Utility is Evolving: While many advanced technologies are promising, their widespread clinical adoption is still developing, with ongoing efforts to standardize analysis and reporting.
Key Results
The paper doesn't present quantitative results from a specific study but rather synthesizes findings from numerous cited studies. Key qualitative findings include:
- Diagnostic Yields: srGS has shown modest incremental diagnostic yields (5-20%) after nondiagnostic ES. RNA sequencing has reported diagnostic rates between 7.5% to 34% for reclassifying VUSs and identifying missing pathogenic variants. DNA methylation analysis has resolved up to 30% of individuals with features suspicious for rare neurodevelopmental conditions.
- Technology Strengths:
- LRS: Excels at resolving complex regions, repeat expansions, and phasing variants.
- OGM: Highly sensitive for detecting large structural variants, inversions, and translocations.
- RNA-seq: Useful for identifying variants affecting splicing or expression, and for identifying candidate genes.
- Clinical Implementation: Many of these advanced technologies are still primarily in the research setting, with limited clinical availability and payor reimbursement.
Limitations and Future Work
- Nascent Technologies: Many of the discussed technologies (e.g., OGM, LRS, untargeted RNA-seq) are not yet widely available clinically, and their full diagnostic utility across various clinical contexts is still being determined.
- Interpretation Challenges: Interpreting variants identified by newer technologies, especially noncoding variants and structural variants, remains a significant challenge due to limited population data and underdeveloped variant callers.
- Cost and Accessibility: Some advanced techniques are more expensive and require substantial computational resources, potentially limiting access.
- Standardization Needed: There's a need for standardized analytical and reporting practices for these emerging technologies to ensure consistent and reliable results.
- Future Directions: The authors emphasize the need for carefully designed studies to determine the optimal "next best test" after negative ES, the collection and biobanking of biospecimens for benchmarking, and the development of new reference genomes. They envision a future where a single data source (like srGS or IrGS), potentially enhanced by concurrent multi-omics, simplifies the diagnostic process. Collaboration between clinicians and researchers is deemed essential for advancing rare disease diagnosis.
Summary updated